Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Why Biogen''s Alzheimer''s drug Aduhelm is so controversial
04:55pm, Tuesday, 04'th Jan 2022 CNBC
Biogen''s Alzheimer''s drug Aduhelm was heralded as a historic triumph against the memory-robbing disease. Now, the company is trying to keep it afloat.
Biogen Licenses Global Rights To Develop, Commercialize SPINRAZA From Ionis Pharma
01:06pm, Tuesday, 04'th Jan 2022 Business Insider Markets
(RTTNews) - Biogen Inc. (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) said Biogen exercised its option to obtain from Ionis a worldwide, royalty-bearing license to develop and commercialize BIIB115/ION306, a preclinical investigational antisense oligonucleotide in development for spinal muscular atrophy. As a part of the option exercise, Biogen
Biogen exercises option with Ionis to develop synthetic nucleotides for spinal muscular atrophy
01:01pm, Tuesday, 04'th Jan 2022 Seeking AlphaWhat's The Controversy Behind Biogen's Alzheimer's Drug
12:39pm, Tuesday, 04'th Jan 2022
The U.S.'s approval of Biogen's Alzheimer's drug Aduhelm was heralded as a historic triumph in the fight against the memory-robbing disease. But so far, Biogen has reported only a fraction of Aduhelm
Why Biogen's Alzheimer's drug Aduhelm is so controversial
11:55am, Tuesday, 04'th Jan 2022
Biogen's Alzheimer's drug Aduhelm was heralded as a historic triumph against the memory-robbing disease. Now, the company is trying to keep it afloat.
Sage Therapeutics: Biogen''s Backing May See It Through
12:49am, Tuesday, 04'th Jan 2022 Seeking Alpha
Mondays Top Analyst Upgrades and Downgrades: Biogen, Cemex, Constellation Brands, Exxon Mobil, Fastly, Hilton Worldwide, McDonalds, Nike, PayPal, Peloton Interactive and More
01:47pm, Monday, 03'rd Jan 2022 24/7 Wall street
Biogen price target cut at Canaccord on pricing, labelling and efficacy concerns
12:59pm, Monday, 03'rd Jan 2022 Seeking AlphaMedicare Trying To Determine Coverage Of Biogen's Expensive Alzheimer's Drug: NYT
06:19am, Monday, 03'rd Jan 2022
Federal officials are struggling with a decision that could determine the future of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm, and whether significant numbers of patients use it. In Janu
Anti-Amyloid Drugs: The Failure Of Success
07:04am, Saturday, 01'st Jan 2022
Anti-Amyloid Drugs: The Failure Of Success
Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung
02:34pm, Thursday, 30'th Dec 2021
Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.
Biogen tanks 8% after Samsung denies report it was in talks to buy the drugmaker
12:06pm, Thursday, 30'th Dec 2021
Samsung's biotech division disputed the report in a filing in South Korea, calling it "not true," according to a translated version.
Citi raises price targets for Ford, GM & Tesla, Biogen stock falls after Samsung rebuts acquisition
11:15am, Thursday, 30'th Dec 2021
Yahoo Finance Live's Brian Sozzi and Julie Hyman break down Citi's move to raise the price targets for key EV players Tesla, Ford, and GM, in addition to looking at the slumps Chinese tech companies a
Don't Panic About These 2 Stocks' Falling Prices on Thursday
09:28am, Thursday, 30'th Dec 2021
There are solid reasons why these companies don't appear to be participating in the market rally.
Why Biogen Shares Are Falling Today
09:20am, Thursday, 30'th Dec 2021
Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after Samsung BioLogics denied that its parent company, Samsung Group, is looking to buy Biogen. Korea Economic Daily reported Wednesday tha
